Results 41 to 50 of about 10,981 (164)

2023 Diabetic Kidney Disease Fact Sheet in Korea [PDF]

Diabetes & Metabolism Journal
Background To investigate the prevalence, incidence, comorbidities, and management status of diabetic kidney disease (DKD) and diabetes-related end-stage kidney disease (ESKD) in South Korea.
Nam Hoon Kim, Mi-Hae Seo, Jin Hyung Jung, Kyung Do Han, Mi Kyung Kim, Nan Hee Kim,   +6 more
doaj   +1 more source

Vasopressin and diabetic nephropathy [PDF]

Current Opinion in Nephrology and Hypertension, 2017
The prevalence of diabetic kidney disease (DKD) is increasing worldwide. Despite major therapeutic advances in the last decades in DKD, the current standard of care let many people progress to severe stages. Vasopressin secretion is increased in diabetes, and its potential role in the onset and progression of DKD is being re-investigated.Recently ...
Roussel, Ronan, Velho, Gilberto, Bankir, Lise   +2 more
openaire   +2 more sources

The Heart and Diabetic Nephropathy

Methodist DeBakey Cardiovascular Journal, 2010
BACKGROUND Diabetic nephropathy represents the most common etiology for stage 5 chronic kidney disease in the United States, resulting in the need for dialysis and transplantation. It is estimated that about one-third of U.S. patients who need renal replacement therapy are diabetics.
Juan Jorge, Olivero, Peter T, Nguyen, Juan Jose, Olivero, Anna, Kagan   +3 more
openaire   +3 more sources

Sodium Glucose Cotransporter-2 Inhibitors in Non-Diabetic Kidney Disease: Evidence in Experimental Models

Pharmaceuticals
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of glucose-lowering agents widely used for the treatment of type 2 diabetes mellitus. A number of clinical trials in type 2 diabetic patients with different degrees of renal impairment have ...
Giovanna Castoldi, Raffaella Carletti, Francesca Barzaghi, Michela Meani, Giovanni Zatti, Gianluca Perseghin, Cira R. T. Di Gioia, Gianpaolo Zerbini   +7 more
doaj   +1 more source

Macular Optical Coherence Tomography Angiography in Nephropathic Patients with Diabetic Retinopathy in Iran: A Prospective Case–Control Study

Ophthalmology and Therapy, 2020
Background Diabetic macular ischemia (DMI) is an important category of diabetic retinopathy (DR) which leads to severe visual loss. Clinically, it is defined by an enlargement of the foveal avascular zone (FAZ) that can be detected by optical coherence ...
Ali Ahmadzadeh Amiri, Majid Reza Sheikh Rezaee, Amir Ahmadzadeh Amiri, Tayebeh Soleymanian, Reza Jafari, Ahmad Ahmadzadeh Amiri   +5 more
doaj   +1 more source

Characterization of diabetic patients with Microalbuminuria

Revista Electrónica Dr. Zoilo E. Marinello Vidaurreta, 2016
Background: diabetic nephropathy is the cause of 10 to 15 % of chronically ill terminal patients and a significant percentage are diagnosed in very advanced stages.Objective: to characterize, from the clinical and epidemiological point of view, the ...
Pilar Laborí Quesada, Alberto Mario Laborí Gallego, Miriam Velázquez Reyes, Alina Dolores Leyva Rojas, Lidia Silvia Sosa Ramos   +4 more
doaj  

Clinical Profile and Risk Factors for Complication of Type 2 Diabetes Mellitus at the National Referral Hospital, Bhutan: A Descriptive Cross‐Sectional Study

Health Science Reports
Background and Aim Globally, diabetes mellitus is a major public health concern affecting 10.5% of the population. Nearly 90% of these people have Type 2 diabetes mellitus (T2DM). In Bhutan, T2DM is prevalent in 5.6% of the population, and around 60% are
Tshering Norbu, Yeshey Dorjey, Sangay Tshering, Namkha Dorji, Guru Prasad Dhakal   +4 more
doaj   +1 more source

Meta-analysis of the Efficacy and Safety of Finerenone in the Treatment of Type 2 Diabetic Nephropathy [PDF]

Zhongguo quanke yixue
Background Finerenone, a nonsteroidal mineralocorticoid antagonist, is a novel therapeutic agent for renal protection in patients with diabetic kidney disease, joining the ranks of angiotensin-converting enzyme inhibitors and sodium-glucose cotransporter
ADILI Tuersun, CHENG Gang
doaj   +1 more source

Diabetic nephropathy

Disease-a-Month, 1998
Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD) and accounts for 35% of the ESRD population in the United States. It results in considerable morbidity, mortality, and expense. The average cost of managing one diabetic patient with ESRD is approximately $50,000 a year.
openaire   +2 more sources

Angiopoietins and diabetic nephropathy [PDF]

Diabetologia, 2016
Diabetic nephropathy is the main cause of end-stage renal failure in the Western world. In diabetes, metabolic and haemodynamic perturbations disrupt the integrity of the glomerular filtration barrier, leading to ultrastructural alterations of the glomeruli, including podocyte foot process fusion and detachment, glomerular basement membrane thickening,
openaire   +3 more sources